Ascendis Pharma Growth Disorders A/S
Stories
-
CHMP adopts positive opinion on Yuviwel for achondroplasia
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 15 October 2026, recommending marketing authorisation for Yuviwel (navepegritide) for children 2 years and older with achondroplasia. The opinion notes that Yuviwel improves annualised growth velocity by 1.49 cm versus placebo in a 52-week trial.